midostaurin,quizartinib,Daunorubicin,Cytarabine
novartis,Daiichi Sankyo
['leusm', 'aml,(-streamline),(-seamless),(-kamloops),(-dreamlike)', 'midostaurin', 'aml,(-streamline),(-seamless),(-kamloops),(-latamleaders)']
congress | #eha2023 | poster adolfo de la fuente, presents results from the retrospective mda-aml-2018-06 study. midostaurin plus ic was associated with a cr rate of 83.4% and a 2-year os rate of 65% in pts with flt3-itd mutated aml in a real-world setting. #leusm 
The AML Hub is an evidence-based online resource on Acute Myeloid Leukemia (AML), for academic researchers and treating clinicians. #leusm